Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SMMT

+ Watchlist+ Portfolio

Summit Therapeutics Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$10.67
52-Week Range
$10.14 – $29.23
Market Cap
$8.40B
P/E (TTM)
—
EPS (TTM)
-1.06
Dividend Yield
0.00%
Advanced Metrics
Price/Book
14.87
PEG Ratio
—
Return on Equity
-220.01%
Return on Assets
-111.99%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
5.99
Debt/Equity
0.04
Total Debt
$19.98M
Free Cash Flow
$-213.92M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$7.79B

Market Snapshot

About

Summit Therapeutics Inc. is a biopharmaceutical company focused on developing innovative antibiotics and precision medicines for serious infectious diseases and oncology. The company is advancing ivonescimab, a bispecific antibody targeting PD-1 and VEGF for cancer treatment. Summit is conducting global clinical trials to address antibiotic-resistant infections and difficult-to-treat cancers.